Aberman to share Pluristem’s expertise in cell therapies at four sessions during the three day conference
HAIFA, ISRAEL, January 27, 2014- Pluristem Therapeutics, Inc. (NasdaqCM: PSTI; TASE: PLTR), a leading developer of placenta-based cell product candidates, today announced the Company’s Chairman and CEO, Zami Aberman, will make two presentations and speak in panel discussions at the 10th Annual Phacilitate Cell & Gene Therapy Forum. The conference will take place on January 27th through 29th, 2014 in Washington D.C.
“We look forward to contributing to this year’s Phacilitate Cell & Gene Therapy Forum by pre- senting our successful strategies in cell therapy development, manufacturing and clinical trials. This gathering, which includes the leaders in cell therapy science, investors, and regulators, is important to advancing the entire cell therapy industry to deliver much needed healthcare solu- tions,” Mr. Aberman stated.
Mr. Aberman will be a panel member on the following sessions:
- Date: Jan 28th, 2014, 10:15AM ET
Panel Discussion
Topic: How are phase I/II C> companies “blocking and tackling” to prepare for commercialization? What are the key questions to ask your development and commercial teams before you reach phase III?
- Date: Jan 28th, 2014, 05:20PM ET
Panel Discussion
Topic: What are the key issues for consideration to assess the viability of such a business model?
Mr. Aberman will be the presenter for the following sessions:
- Date: Jan 29th, 2014, 10:55AM ET
Topic: 3D culturing of MSC opens new possibilities for screening, toxicology and diag- nostics
- Date: Jan 29th, 2014, 12:45PM ET
Focus Session 3
Case Study: The challenges in the design and implementation of a multi-national, FDA/EMA approved PAD clinical study
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company’s patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic in- flammatory and ischemic diseases. PLX cells are grown using the company’s proprietary 3D micro-environmental technology and are an “off-the-shelf” product that requires no tissue matching prior to administration.
Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institu- tions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking state- ments. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market require- ments; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific com- munity; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new tech- nologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Plu- ristem, reference is made to Pluristem’s reports filed from time to time with the Securities and Exchange Commission.
Contact:
Pluristem Therapeutics Inc.: Karine Kleinhaus, MD, MPH
Director of Investor Relations 1-914-512-4109
Daya Lettvin
Investor & Media Relations Director
+972-54-674-5580
